(:BIOC)
Business Focus: N/A
Sep 21, 2023 08:00 am ET
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective
Sep 11, 2023 09:31 am ET
Thinking about buying stock in Tivic Health Systems, Axcella Health, Biocept, Aravive, or Uranium Royalty Corp?
NEW YORK, Sept. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TIVC, AXLA, BIOC, ARAV, and UROY.
Sep 08, 2023 08:00 am ET
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plu
Sep 05, 2023 08:00 am ET
Biocept to Participate in the H.C. Wainwright Global Investment Conference
Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the
Aug 25, 2023 08:00 am ET
Biocept to Hold Business Update Conference Call on August 30, 2023
Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions.
Aug 14, 2023 04:05 pm ET
Biocept Reports Second Quarter 2023 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
Aug 14, 2023 08:00 am ET
Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the
Jul 13, 2023 06:15 pm ET
Biocept Announces the Passing of Board Chair M. Faye Wilson
Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and express their gratitude for her many contributions to Biocept.
Jun 20, 2023 04:15 pm ET
Biocept Names Antonino Morales as President and Chief Executive Officer
Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept’s interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2
Jun 14, 2023 04:05 pm ET
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept’s discussion will be hosted by Maxim Grou
Jun 05, 2023 08:00 am ET
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology
Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago showing the ability of CNSide™ to detect rates of leptomeningeal metastases (LM) compared with standar
May 24, 2023 08:39 pm ET
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock a
May 17, 2023 08:00 am ET
Biocept Announces One-for-Thirty Reverse Stock Split
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. Biocept’s comm
May 10, 2023 04:05 pm ET
Biocept Reports First Quarter 2023 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update.
Apr 17, 2023 04:10 pm ET
Biocept Reports 2022 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update.
Mar 24, 2023 08:00 am ET
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). This first patient was seen at the UT Southwestern Medical Center, one of the largest and most respected hospitals in the nation.
Mar 01, 2023 08:00 am ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees. The inducement stock options have a grant date of February 28, 2023 and were granted as inducements material t
Jan 06, 2023 06:55 am ET
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process.
Nov 21, 2022 04:05 pm ET
Biocept Reports Third Quarter 2022 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update.
Nov 18, 2022 08:00 am ET
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experien
Nov 16, 2022 08:00 am ET
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic pilot study to evaluate the cerebrospinal fluid tumor and immune cell microenvironment in patients with metastatic breast cancer and brain metastases and/
Nov 10, 2022 04:05 pm ET
Biocept Reports Second Quarter 2022 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business update.
Oct 19, 2022 08:00 am ET
Biocept to Present at the LD Micro Main Event XV
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time (5:30 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
Oct 17, 2022 08:00 am ET
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of
Oct 14, 2022 08:00 am ET
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m. Eastern time featuring case studies presented by leading neuro-oncologists who have used the company’s CNSide assay in the management of patients with confirmed or suspected centra
Oct 06, 2022 08:00 am ET
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Eastern time featuring case studies presented by leading neuro-oncologists who have used the company’s CNSide assay in the management of patients with confirmed or suspected central nervo
Aug 31, 2022 04:31 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees. The inducement stock options have a grant date of August 31, 2022 and were granted as inducements material
Aug 22, 2022 04:15 pm ET
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising Biocept that it was not in compliance with Nasdaq’s continued listing requirements unde
Aug 16, 2022 08:00 am ET
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended June 30, 2022, whic
Jun 27, 2022 08:00 am ET
Biocept Appoints RSM as Independent Auditor
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th st
Jun 22, 2022 07:30 am ET
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, and Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic...
Jun 07, 2022 08:00 am ET
Biocept to Hold Business Strategy Conference Call Today
Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.
May 23, 2022 04:05 pm ET
Biocept Reports First Quarter 2022 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.
May 16, 2022 04:05 pm ET
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended March 31, 2022
Apr 08, 2022 04:05 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand,
Apr 06, 2022 08:00 am ET
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update.
Mar 31, 2022 06:15 pm ET
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million.
Mar 18, 2022 08:00 am ET
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022. Management will not hold an investment community conference call with the reporting of 2021 fourth quar
Mar 08, 2022 08:17 am ET
Biocept Appoints Philippe Marchand as Chief Operating Officer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today. Dr. Marchand will be responsible for advancing the company’s strategic and operational objectives, including all laboratory operations of its CNSide c
Mar 04, 2022 08:00 am ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor, its new Senior Vice President, General Counsel and Chief Compliance Officer. The inducement stock option has a grant date
Feb 22, 2022 04:17 pm ET
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its
Feb 16, 2022 04:05 pm ET
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson
Feb 10, 2022 08:17 am ET
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience, Taylor will lead essential aspects of legal, compliance and privacy efforts, and will report to Biocept President and CEO Michael Nall.
Jan 21, 2022 08:00 am ET
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant. Biocept continues to serve the community with high-quality testing, having received more than 40,000 samples for COVID-19 testing since the
Jan 04, 2022 08:00 am ET
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Biocept presentation can be accessed on the
Dec 09, 2021 08:17 am ET
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, presented a study demonstrating the ability of its CNSide™ assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD). The
Nov 22, 2021 12:56 pm ET
Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression
SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services. This novel test is highly sensitive and specific, and can quantify a patient's SARS-CoV-2 viral load to determine the active infection level.
Nov 22, 2021 08:17 am ET
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions. This new assay expands the company’s COVID-19 testing program, which began in June
Nov 18, 2021 02:45 pm ET
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology. (instead of CNSide detected CSF tumor cells in all nine measurements taken, compared to five of nine using cytology.)
Nov 18, 2021 08:17 am ET
Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case series showing that its CNSide™ cerebrospinal fluid assay helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptome
Nov 15, 2021 04:05 pm ET
Biocept Reports Third Quarter 2021 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.
Nov 09, 2021 08:17 am ET
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the publication of a study showing that the addition of Switch-Blocker™ technology to common PCR-based liquid biopsy assays significantly increased sensitivity in detecting rare cancer mutations. The
Nov 08, 2021 08:00 am ET
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions a
Oct 06, 2021 08:00 am ET
Biocept to Present at the LD Micro Main Event on October 13
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Ho
Sep 22, 2021 08:17 am ET
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has implemented its COVID-19 testing services at more than 30 community college campuses across California, streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 test
Sep 22, 2021 07:00 am ET
Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - September 22, 2021) - Biocept (NASDAQ: BIOC) will be presenting at the Benzinga Healthcare Small Cap Conference being held September 29-30, 2021. We invite our shareholders and all interested parties to explore healthcare small cap investment opportunities through two days of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/healthcare/
Sep 21, 2021 08:17 am ET
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data on its Target Selector™ assay formats for the ultra-sensitive detection of KRAS mutations using Switch-Blocker™ technology, which provides advantages for the assessment of therapeutic tumor response and is cost effective for serial monitoring. Biocept’s presentation is on Sept. 23 at 2:00 p.m. EDT at the Third Annual
Sep 07, 2021 08:00 am ET
Biocept to Present at Four Virtual Investor Conferences in September
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:
Aug 31, 2021 08:00 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees. These inducement stock options have a grant date of August 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 19, 2021 10:35 am ET
Thinking about buying stock in Sonnet BioTherapeutics, Biocept, ReShape Lifesciences, Tencent Music Entertainment, or Cleveland-Cliffs?
NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, BIOC, RSLS, TME, and CLF.
Aug 19, 2021 08:34 am ET
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s cerebrospinal fluid assay, CNSide™, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes and extend life expectancy.
Aug 16, 2021 04:05 pm ET
Biocept Reports Second Quarter 2021 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2021 and provides a business update.
Aug 09, 2021 08:00 am ET
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021. The Company will host a conference call for the investment community to discuss the results and answer
Aug 03, 2021 08:17 am ET
Biocept Names David Karlander as Senior Vice President of Commercial Operations
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years of industry experience, Karlander will lead all aspects of commercialization, including sales, marketing and reimbursement, and will report to Biocept President and CEO Michael Nall.
Jul 21, 2021 08:17 am ET
Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, has received a positive final Local Coverage Determination (LCD) that expands Medicare coverage for use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). This coverage determination from the Centers for Medicare & Med
Jul 20, 2021 08:17 am ET
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to its Board of Directors, effective immediately. The company also named Director Samuel D. Riccitelli as Chairman of the Board, succeeding long-time Chair David Hale and interim Chair M. Faye Wilson, both of whom remain Directors.
Jul 19, 2021 08:00 am ET
Biocept to Participate in Two July Investment Conferences
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences:
Jul 06, 2021 08:27 am ET
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular diagnostic assays and services, has been awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA (ctDNA) using real-time PCR and associated analysis methods. The patent (No. 2252447) is titled Methods for Detecting Nucleic Acid Sequen
Jun 28, 2021 08:05 am ET
Biocept Joins the Russell Microcap® Index
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021.
Jun 22, 2021 09:31 am ET
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV.
Jun 22, 2021 08:17 am ET
Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™ NGS-based liquid biopsy targeted lung cancer panel. Quest Diagnostics is the leading provider of diagnostic
Jun 15, 2021 08:17 am ET
Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020. The samples are processed using Biocept’s RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular
Jun 09, 2021 08:37 am ET
Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, and CLEARED4, a market leader in pandemic health and safety solutions, have partnered to develop a system for tracking and managing COVID-19 testing requirements and test results for Biocept customers.
Jun 03, 2021 08:00 am ET
Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).
Jun 02, 2021 04:05 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees. These inducement stock options have a grant date of May 31, 2021, and were granted as inducements mate
May 12, 2021 04:05 pm ET
Biocept Reports First Quarter 2021 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2021 and provides a business update.
May 05, 2021 08:00 am ET
Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021. The Company will host a conference call for the investment community to discuss the results and answer questio
Apr 28, 2021 08:17 am ET
Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation for California Community Colleges to make COVID-19 testing available to the 116 California community colleges and their more than 2.1 million students.
Apr 21, 2021 08:17 am ET
Biocept Announces Full Commercial Launch of CNSide™ Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has announced the full commercial launch of
Apr 14, 2021 08:05 am ET
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing. These samples are processed using Biocept’s RT-PCR technology at its CLIA-certified, CAP-accredited high-
Apr 07, 2021 04:05 pm ET
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company’s proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept’s CSF assay provides enhanced sensitivity compar
Apr 01, 2021 05:00 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees. These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 01, 2021 08:05 am ET
Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the use of the Company’s proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain
Mar 29, 2021 04:05 pm ET
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2020 and provides a business update.
Mar 22, 2021 08:00 am ET
Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021. The Company will host a conference call for the investment community to discuss the results and answe
Mar 09, 2021 07:00 am ET
Biocept to Participate in Three Virtual Investment Conferences in March
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in three upcoming virtual investment conferences:
Mar 03, 2021 04:05 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees. These inducement stock options have a grant date of February 28, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
Mar 02, 2021 08:07 am ET
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
Aegea Biotechnologies, Inc., an innovative life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies, and
Feb 23, 2021 08:07 am ET
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean BioDiagnostics Inc. to research the ability of Biocept’s Target Selector™ molecular assay to determine EGFR status in non-small cell lung cancer (NSCLC) patients. The research will be conducted in an independent patholog
Feb 16, 2021 08:00 am ET
Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects mutations in up to 50% of tissue biopsy specimens, from patients diagnosed with non-small cell lung cancer, that were deemed quantity not sufficient (QNS). The study will
Feb 03, 2021 08:00 am ET
Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more than 250,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laborato
Feb 02, 2021 04:05 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 86,720 shares of its common stock to 5 new employees
Jan 12, 2021 08:00 am ET
Biocept Issues Letter to Stockholders
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:
Jan 04, 2021 07:05 am ET
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning on January 11, 2021 at 6:00 a.m. Eastern time.
Dec 31, 2020 04:29 pm ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 83,120 shares of its common stock to 14 new employees. These inducement stock options have a grant date of December 31, 2020, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Li
Dec 30, 2020 07:05 am ET
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has entered into laboratory services agreements with independent physician associations (IPAs) providing physicians and patients in-network access to Biocept's full array of Target Selector™ liquid biopsy oncology assays and services. Both IPAs are headquartered in San Diego and combined serve more than 70,000 covered lives
Dec 14, 2020 07:00 am ET
Biocept Provides Business Update
SAN DIEGO, Dec. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has received more than 150,000 samples for COVID-19 RT-PCR testing to date and has continued to report the vast majority of results to customers within 48 hours of receiving a sample. The Company also announces the successful relocation to its new corporate headquarters and molecular laboratory facility in San Diego.
Dec 10, 2020 07:00 am ET
Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center
SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The results were featured yesterday in a poster presentation by Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women's Mal
Dec 01, 2020 10:30 am ET
While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately
PHILADELPHIA, Dec. 1, 2020 /PRNewswire/ -- EIR Healthcare today announces the launch of MedModLabs, its modular healthcare initiative dedicated to expanding COVID-19 testing access by building top-of-the-line mobile, prefabricated sampling and testing facilities more cost-effectively and time efficiently. EIR's new mobile COVID-19 testing unit solutions, developed in concert with partners like Biocept (Nasdaq: BIOC) and Measurement Vault, are designed to bring testing directly to people, offering non-invasive oral swab tests that deliver results in 1-2 business days, no prescription required
Nov 20, 2020 07:00 am ET
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central N
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease. The findings indicate that Target Selector™ CSF assays are a viable and sensitive platform for circulating tumor cell (CTC) detection and molecular analysis compared to the c
Nov 17, 2020 07:05 am ET
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
SAN DIEGO, Nov. 17, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective study using Target Selector™ testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium® (SABCS) on December 9, 2020.
Nov 12, 2020 03:05 pm ET
Biocept Reports Third Quarter 2020 Financial Results
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, reports financial results for the three and nine months ended September 30, 2020 and provides an update on its business progress.
Nov 12, 2020 09:45 am ET
Thinking about buying stock in IMAC Holdings, Advanced Micro Devices, Biocept, Li Auto, or EuroDry?
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMAC, AMD, BIOC, LI, and EDRY.
Nov 12, 2020 07:05 am ET
Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory.
Nov 09, 2020 07:05 am ET
Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Hong Kong Patent No. 1188285 entitled, METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION. This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumor cells (CTCs).
Nov 05, 2020 07:05 am ET
Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Japanese Patent No. 6771010 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers devices for the detection of any target of interest, including circulating tumor cells (CTCs) that are shed into the blood stream by solid tumors where a binding entity, including antibodies or mixt
Nov 04, 2020 07:00 am ET
Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the market closes on Thursday, November 12, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Oct 29, 2020 08:05 am ET
Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory.
Oct 21, 2020 08:00 am ET
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately. Mr. Riccitelli is joining the Board ahead of the planned retirement of Bruce A. Huebner, who will retire from the Biocept Board of Directors on November 30, 2020.
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 24, 2020 08:00 am ET
Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan, M.D. as...
Aug 20, 2020 08:30 am ET
Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present...
Aug 19, 2020 08:00 am ET
Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with...
Aug 06, 2020 09:31 am ET
Thinking about buying stock in Biocept Inc, MediciNova Inc, Plug Power, IZEA Worldwide, or Teva Pharmaceutical?
NEW YORK, Aug. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, MNOV, PLUG, IZEA, and TEVA.
Aug 06, 2020 08:00 am ET
Biocept Announces Agreement with Aegea Biotechnologies to Develop New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc., an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies, announce a development agreement focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus. The COVID-
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 04, 2020 08:00 am ET
Biocept to Release Second Quarter 2020 Financial Results and Host Investor Conference Call on August 12, 2020
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and six months ended June 30, 2020 after the market closes on Wednesday, August 12, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Aug 03, 2020 10:35 am ET
Thinking about buying stock in Microsoft Corp, Biocept Inc, Delta Air Lines, Carnival Corp, or Nokia?
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, BIOC, DAL, CCL, and NOK.
Aug 03, 2020 08:00 am ET
Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has received more than 7,000 and processed more than 6,500 COVID-19 specimens to date using RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular lab. The Company has distributed nearly 12,000 COVID-19 PCR specimen collection kits to date, and has approximately 18,000 additional collection kits assembled and available for immediat
Jul 16, 2020 08:05 am ET
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares
SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis) both have recommended that stockholders vote in favor of Biocept's proxy proposal to authorize a reverse stock split of Biocept's common stock, as further described in Biocept's Proxy Statement for its 2020 Annual Meeting of Stockholders. This item is Prop
Jul 08, 2020 10:45 am ET
Thinking about buying stock in Biocept Inc, Nokia, Ford Motor Company, Nikola Corp, or Tonix Pharmaceuticals?
NEW YORK, July 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, NOK, F, NKLA, and TNXP.
Jun 30, 2020 08:05 am ET
Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
SAN DIEGO, June 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it has been awarded Canadian Patent 2812291, entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION. This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumor cells (CTCs), and from a biological fluid. The issuance of this patent increases Biocept's total patent award
Jun 24, 2020 08:05 am ET
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed care provider agreement with Medical Cost Containment Professionals, LLC (MCCP) to process out-of-network claims for Biocept's Target Selector™ liquid biopsy testing. MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide.
Jun 22, 2020 10:35 am ET
Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC.
Jun 22, 2020 08:05 am ET
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 (COVID-19) for physician ordering. Collected specimens will be shipped overnight to Biocept's high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering physicians in an e
Jun 17, 2020 10:30 am ET
Thinking about buying stock in Biocept, TOP Ships, Aclaris Therapeutics, Seanergy Maritime, or InnerWorkings?
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, TOPS, ACRS, SHIP, and INWK.
Jun 15, 2020 10:30 am ET
Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?
NEW YORK, June 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, HTZ, BIOC, EDSA, and ADMP.
Jun 05, 2020 08:05 am ET
Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location
SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. The move is expected to be completed by 2020 year end.
May 29, 2020 08:30 am ET
Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
SAN DIEGO, May 29, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the presentation of data affirming the ability of its Target Selector™ platform to identify potentially actionable mutations in the cerebrospinal fluid of patients whose cancer has metastasized to the central nervous system. The data were presented today by Kevin Kalinsky, MD, MS, associate professor of medicine at Columbia University Vagel
May 27, 2020 09:31 am ET
Thinking about buying stock in Biocept, Celsion Corp, Tilray, Altimmune, or Ford?
NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, CLSN, TLRY, ALT, and F.
May 20, 2020 08:05 am ET
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air" hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 12:00 p.m. Eastern time (9:00 a.m. Pacific time).
May 14, 2020 08:05 am ET
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
SAN DIEGO, May 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of a Target Selector™ molecular assay research-use-only (RUO) kit for the detection of BRAF mutations. Biocept's molecular assay kits offer superior sensitivity compared with next generation sequencing (NGS) panels for the detection of biomarkers of key oncogene mutations from a blood sample.
May 13, 2020 04:05 pm ET
Biocept Reports First Quarter 2020 Financial Results
SAN DIEGO, May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its business progress.
Apr 29, 2020 08:05 am ET
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020
SAN DIEGO, April 29, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three months ended March 31, 2020 after the market closes on Wednesday, May 13, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Apr 28, 2020 08:05 am ET
Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the award of CE (Conformité Européene)-IVD Mark for its Target Selector™ molecular assay EGFR Kit. The CE Mark confirms that the Company's Target Selector™ kit products meet the requirements of the European In-Vitro Diagnostic Devices Directive (98/79/EC) and allows Biocept to commercialize its kits throughout the European Union an
Apr 20, 2020 08:05 am ET
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
SAN DIEGO, April 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits that can allow molecular laboratories around the world to utilize Biocept's Target Selector™ molecular assay kits to detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor
Apr 14, 2020 09:00 am ET
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
SAN DIEGO, April 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on April 14, 2020 it entered into a securities purchase agreement with several institutional investors for the issuance and sale of 22,300,000 shares of its common stock at a price of $0.46 per share, for aggregate gross proceeds of approximately $10.3 million, in a registered direct offering.
Apr 09, 2020 07:17 pm ET
Biocept to Begin COVID-19 Testing
SAN DIEGO, April 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020.
Apr 09, 2020 08:05 am ET
Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
SAN DIEGO, April 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted Brazil Patent No. BR112013028296-7, titled, METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for the Switch-Blocker technology that is core to Biocept's Target Selector™ assays for ctDNA analysis using real-time PCR, Sanger sequencing and next-generati
Apr 02, 2020 08:05 am ET
Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform
SAN DIEGO, April 2, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted Australia Patent number: 2017268486, titled, METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for Biocept's Primer-Switch technology that is useful for ctDNA analysis using real-time PCR and associated analysis methods, including next-generation sequen
Mar 26, 2020 09:31 am ET
Thinking about buying stock in Biocept, Chembio Diagnostics, FuelCell Energy, General Motors, or Slack Technologies?
NEW YORK, March 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, CEMI, FCEL, GM, and WORK.
Mar 26, 2020 08:05 am ET
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
SAN DIEGO, March 26, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a second California-based independent physician association (IPA) to provide its Target Selector™ liquid biopsy assay services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel,
Mar 25, 2020 04:05 pm ET
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
SAN DIEGO, March 25, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2019, and provides an update on its business progress.
Mar 18, 2020 08:05 am ET
Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020
SAN DIEGO, March 18, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and 12 months ended December 31, 2019 after the market closes on Wednesday, March 25, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Nov 13, 2019 03:05 pm ET
Biocept Reports Third Quarter 2019 Financial Results
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and nine months ended September 30, 2019, and provides an update on its business progress.
Nov 07, 2019 07:05 am ET
Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe
SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conformité Européene) IVD Marks and availability of its CEE-Sure® Blood Collection Tube and CEE-Sure® Sample Collection Shipping Kit in Europe. The CE Marks confirm that the Company's CEE-Sure® products, designed to collect and transport blood and other liquid biopsy specimens, meet the requirements of the European In-Vitro Diagno
Nov 06, 2019 07:05 am ET
Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019
SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and nine months ended September 30, 2019 after the market closes on Wednesday, November 13, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Nov 04, 2019 07:05 am ET
Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that clinical data highlighting performance of the Company's Target Selector™ tests and kits for detecting actionable oncology biomarkers will be presented at the 2019 Association for Molecular Pathology (AMP) Annual Meeting being held November 7-9, 2019 at the Baltimore Convention Center in Baltimore, Md. Information about the AMP M
Oct 07, 2019 08:05 am ET
Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed journal article featuring analytical validation results demonstrating the high sensitivity of the Company's Target Selector™ testing for EGFR, BRAF, and KRAS mutations in plasma circulating tumor DNA (ctDNA). The article was published in the journal, PLOS ONE, Volume 14, October 2019, and will also b
Oct 03, 2019 08:05 am ET
Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded South Korean Patent No. 2010601, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for the Company's Switch-Blocker technology, which is core to Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and
Sep 03, 2019 08:05 am ET
Biocept to Present at Two Investment Conferences in September
SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at two upcoming investment conferences:
Aug 22, 2019 08:05 am ET
High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that clinical data highlighting real-world performance of the Company's Target Selector™ platform for detecting actionable biomarkers in lung cancer patients will be presented at the 2019 IASLC World Conference on Lung Cancer being held September 7-10, 2019 at the Fira Gran Via Exhibition and Conference Center in Barcelona, Spain. Th
Aug 13, 2019 08:05 am ET
Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
SAN DIEGO, Aug. 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded three distinct patents in the U.S., Canada, and Europe: U.S. Patent No. 10,369,568 entitled CELL SEPARATION USING MICROCHANNEL HAVING PATTERNED POSTS; Canadian Patent No. 2,756,493 entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS; and European Patent No. 2,619,588 entitled METHODS AND REAGENTS FOR SI
Aug 12, 2019 04:05 pm ET
Biocept Reports Second Quarter 2019 Financial Results
SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six months ended June 30, 2019, and provides an update on its business progress.
Aug 05, 2019 08:05 am ET
Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and six months ended June 30, 2019 after the market closes on Monday, August 12, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Jul 22, 2019 08:05 am ET
Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into a Laboratory Services Provider Agreement with Beacon Laboratory Benefit Solutions, Inc. (BeaconLBS®), a nationally recognized premier provider of laboratory benefit management technology solutions to health and managed care companies in the United States. BeaconLBS administers laboratory benefit managemen
May 21, 2019 09:31 am ET
Thinking about buying stock in Apple, Biocept, Canopy Growth, Sprint, or Uber?
NEW YORK, May 21, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BIOC, CGC, S, and UBER.
May 20, 2019 08:05 am ET
Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the commercial launch of Target Selector™ NGS Lung Panel, the Company's multi-gene liquid biopsy panel specifically developed for lung cancer. This product runs on Thermo Fisher Scientific's Ion Torrent™ next generation sequencing (NGS) platform. The Target Selector™ NGS Lung Panel will be marketed to physicians and researchers, and c
May 08, 2019 04:05 pm ET
Biocept Reports First Quarter 2019 Financial Results
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three months ended March 31, 2019 and provides an update on its business progress.
May 01, 2019 08:05 am ET
Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
SAN DIEGO, May 1, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three months ended March 31, 2019 after the market closes on Wednesday, May 8, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Mar 28, 2019 04:05 pm ET
Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
SAN DIEGO, March 28, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2018, and provides an update on its business progress.
Mar 26, 2019 08:05 am ET
Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment
SAN DIEGO, March 26, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will begin commercializing its recently expanded pathology partnership platform, EmpowerTC, to urology and uropathology practices. Biocept has expanded the capability of EmpowerTC to perform biomarker tests that can aid physicians and pathologists in the management of patients diagnosed with prostate cancer. Such tests inclu
Mar 21, 2019 08:05 am ET
Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019
SAN DIEGO, March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial results for the three and 12 months ended December 31, 2018, after the market closes on Thursday, March 28, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Mar 18, 2019 08:05 am ET
Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device
SAN DIEGO, March 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Japanese Patent No. 6463668 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers a microchannel device and antibodies for the capture of rare cells of interest, including CTCs that are shed into the blood stream by solid tumors. Biocept believes the newly granted patent has cl
Mar 15, 2019 09:00 am ET
Biocept Announces Pricing of $8.2 Million Registered Direct Offering
SAN DIEGO, March 15, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $8.2 million of its common stock in a registered direct offering and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one shar
Mar 13, 2019 08:05 am ET
Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services
SAN DIEGO, March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has expanded its pathology partnership platform, EmpowerTCTM, to now offer local pathologists the ability to analyze prognostic and predictive markers on CTCs from a liquid biopsy using immunocytochemistry (ICC) methods. This new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Bi
Mar 04, 2019 07:05 am ET
Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting
SAN DIEGO, March 4, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that its abstract demonstrating the ability of the Company's Target Selector™ liquid biopsy test to detect ESR1 mutations with high sensitivity has been accepted for a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 at the Georgia World Congress Center i
Feb 27, 2019 07:05 am ET
Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer
SAN DIEGO, Feb. 27, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will collaborate with Providence St. Joseph Health, Southern California, and its wholly owned affiliates Providence Saint John's Health Center and the John Wayne Cancer Institute, to conduct a study to validate the use of cerebrospinal fluid (CSF) as a specimen type with Biocept's Target Selector™ liquid biopsy platform.
Feb 20, 2019 07:05 am ET
Biocept Issues Letter to Stockholders
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:
Feb 08, 2019 07:45 am ET
Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
SAN DIEGO, Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to 6,250,000 shares of the Company's common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $1.20 per share and warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering e
Feb 07, 2019 07:42 am ET
Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the world for both research and clinical applications. Under the agreement, Agiomix plans to validate Biocept's patented and proprietary liquid biopsy technology in order to perform testing for the detection of tumor biomarkers. The testing will be performed in Agiomix's UAE-based diagnostics laboratory and wi
Feb 05, 2019 07:05 am ET
Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed article featuring a case series of three patients indicating the clinical utility of Biocept's Target Selector™ circulating tumor DNA (ctDNA) testing in the management of patients with advanced non-small cell lung cancer (NSCLC). In each of the three patient cases, Biocept's liquid biopsy testing det
Jan 28, 2019 07:05 am ET
Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
SAN DIEGO, Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits, which are intended to enable molecular laboratories around the world to utilize Biocept's Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing. Biocept's Target Selector™ platform is patent protected in the United States and in 10 major international
Jan 18, 2019 08:00 am ET
Biocept Announces Pricing of $2.2 Million Registered Direct Offering
SAN DIEGO, Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering. The purchase price for one share of common stock will be $2.25.
Jan 17, 2019 08:31 am ET
Thinking about buying stock in Alcoa, Biocept, First Data Corp, The Meet Group or Netflix?
NEW YORK, Jan. 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AA, BIOC, FDC, MEET, and NFLX.
Dec 19, 2018 08:31 am ET
Thinking about buying stock in Aurora Cannabis Inc, Biocept Inc, Cronos Group Inc, General Mills, Inc., or Pfizer Inc.?
NEW YORK, Dec. 19, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BIOC, CRON, GIS, and PFE.
Dec 18, 2018 07:05 am ET
Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in On
SAN DIEGO, Dec. 18, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease by applying artificial intelligence (AI) to clinical laboratory diagnostics. Under the agreement, Biocept will supply de-identified data from its liquid biopsy testing to Prognos, which will leverage its AI capabiliti
Nov 13, 2018 03:05 pm ET
Biocept Reports Third Quarter 2018 Financial Results
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and nine months ended September 30, 2018, and provides an update on its business progress.
Nov 06, 2018 07:05 am ET
Nov 05, 2018 07:05 am ET
Biocept Announces New Executive Hires to its Sales and Marketing Organization
SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointments of Scott Nicholson as Vice President of Sales - US and Cory Dunn as Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets, and Dunn has over 15 years of commercial marketing experience in the life sciences i
Oct 23, 2018 08:05 am ET
Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30
SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth Conference on October 30, 2018 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). The conference is being held in Jupiter, Fla.
Oct 18, 2018 08:05 am ET
Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted Japanese Patent No. 6404118, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for the Company's Switch-Blocker technology which is core to Biocept's Target Selector™ assays for analysis using real-time PCR, Sanger sequencing and next-generatio
Sep 25, 2018 08:05 am ET
Biocept to Present at The MicroCap Conference in New York on October 2
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at The MicroCap Conference on October 2, 2018, at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). The conference is being held at the Essex House in New York City.
Sep 24, 2018 08:05 am ET
Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Hong Kong Patent No. HK1222901 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers the use of antibodies for the capture of any cell of interest, including circulating tumor cells (CTCs), within a microchannel.
Sep 21, 2018 07:00 am ET
Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and concurrent private placement at market. The combined
Sep 10, 2018 08:05 am ET
Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer. Mr. Hendrick brings to Biocept over 25 years of sales and commercial leadership experience in the healthcare industry, with recent senior level commercial and operational positions in the clinical diagnostics segment.
Sep 06, 2018 08:05 am ET
Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster presentations featuring clinical data sets using its Target Selector™ liquid biopsy platform will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. The conference is being held September 23-26, 2018 in Toronto at the Metro Toronto Convention Centre
Aug 23, 2018 10:30 am ET
Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
PITTSBURGH and SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help oncologists improve the diagnosis and treatment of patients with non-small cell lung cancer (NSCLC). The goals of the collaboration are to improve health outcomes by using liquid biopsy to more rapidly assess a patient's molecular status and select appropriate therapy, while reducing the overall cost of care.
Aug 14, 2018 04:05 pm ET
Biocept Reports Second Quarter 2018 Financial Results
SAN DIEGO, Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six months ended June 30, 2018, and provides an update on its business progress.
Aug 09, 2018 04:05 pm ET
Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial results for the three and six months ended June 30, 2018, after the market closes on Tuesday, August 14, 2018. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Aug 09, 2018 08:05 am ET
Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced rights offering (the "Rights Offering") expired on Wednesday, August 8, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $11.6 million in gross proceeds. The results of the
Aug 06, 2018 08:05 am ET
Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector™ testing in patients diagnosed with non-small cell lung cancer (NSCLC). As part of the agreement, the Company's liquid biopsy testing will be used to profile patients who
Aug 02, 2018 08:05 am ET
Biocept Awarded Patent in Canada for its Target Selector CTC Platform
SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Canadian Patent No. 2,658,336 entitled, Detection or Isolation of Target Molecules Using a Microchannel Apparatus. The issued patent covers the use of Biocept's proprietary microchannels for the capture and detection of any target of interest. These targets include proteins and nucleic acids, as well as the ca
Jul 31, 2018 08:05 am ET
European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
SAN DIEGO, July 31, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted European Patent No. 2,705,162, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection in seven European countries and is core to Biocept's Target Selector™ assays for ctDNA analysis using real-time PCR, Sanger sequencing and next-generation seq
Jul 23, 2018 08:05 am ET
Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
SAN DIEGO, July 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors. These studies will use Biocept's Target Selector™ liquid biopsy assays to detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) and compare results with findings from CT or P
Jul 19, 2018 09:00 am ET
Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
SAN DIEGO, July 19, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today issued a reminder to shareholders that the record date of its proposed rights offering is Monday, July 23, 2018. To be a shareholder of record on the record date, ownership of Biocept stock must occur by market close on Thursday, July 19, 2018 to account for settlement.
Jul 13, 2018 08:05 am ET
Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
SAN DIEGO, July 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. All diagnostic testing services under this agreement will be performed in Bioc
Jul 12, 2018 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Biocept, Chesapeake Energy, Papa John's Int'l, Inc. or Twitter?
CHICAGO, July 12, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BIOC, CHK, PZZA, and TWTR.
Jul 11, 2018 09:00 am ET
Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SAN DIEGO, July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of Biocept's common stock by Thursday, July 19, 2018 to be considered a stockholder of record on Mo
Jun 25, 2018 08:05 am ET
Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.